Treatments & Techniques

The Conversation Around De-escalation in Breast Cancer Surgery

Research continues to show that more aggressive surgical treatment is not always better for some breast cancer patients, yet many physicians and patients continue to opt for the maximalist approach. Is change possible?


Quest for Medical Therapy for Alzheimer’s Disease Continues

Clinical trials for disease-modifying therapy for Alzheimer’s disease are underway.


Novel Monoclonal Antibody Could Transform High-Risk Neuroblastoma Treatment

Researchers at St. Jude Children’s Research Hospital found that adding a novel anti-disialoganglioside GD2 (anti-GD2) monoclonal antibody to the standard therapy for children newly diagnosed with high-risk neuroblastoma significantly enhanced response to treatment and improved survival. Their findings could be transformative if additional studies can produce similar results.


Substance Use Guidelines Focus on Evidence-Based Care

New AMA Substance Use & Pain Care Task Force recommendations aim to improve opioid prescribing and addiction treatment.


Implications of Physical Activity and Health Measures in Older Men

Based on the Osteoporotic Fractures in Men Study, higher physical activity is associated with an increase in functional strength and mobility in older men, as well as decreased risk of hospitalization. Evidence suggests incorporating physical activity into primary care.


Vertebral Body Tethering Showing Promise for Some Patients

Vertebral body tethering (VBT), a surgical alternative to spinal fusion for patients with severe scoliosis, is not in widespread use, but research shows it could help certain populations, young athletes in particular. Still, there are drawbacks.


GERD: Advances in Treatment and Prevention

Recent trials and studies have led to promising insights and new options for the management and treatment of GERD for some patients.


That’s News

Two New Weight Loss Treatments Show Promise

Over the summer, the FDA approved Wegovy injections for chronic weight management, the first such drug approved since 2014. Manufactured by Novo Nordisk, the drug works by mimicking the hormone glucagon-like peptide-1 (GLP-1), which helps regulate...


Denosumab for Bone Density Loss: Benefits vs. Risks

For some patients with degenerative bone disorders, the human monoclonal antibody denosumab can reduce BMD loss and the risk for fractures. Ongoing research is revealing the advantages and risks.